First case series on the use of calcipotriol?betamethasone dipropionate for morphoea

Dytoc, Marlene; Kossintseva, Irèn; Ting, Patricia T.

doi:10.1111/j.1365-2133.2007.07971.x

Cited by 51 publications

(28 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…61 In an open-label prospective study of 12 patients with active plaque or linear morphea, twice daily occluded topical calcipotriene used for 3 months resulted in a statistically significant decrease in erythema, dyspigmentation, telangiectasia, and induration. 62 Batchelor et al 63 recently carried out a prospective, lesion-controlled study of photodynamic therapy in the treatment of morphea.…”

Section: Ultraviolet Lightmentioning

confidence: 98%

Update on morphea

Fett¹,

Werth²

2011

Journal of the American Academy of Dermatology

154

View full text Add to dashboard Cite

Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.

show abstract

Section: Ultraviolet Lightmentioning

confidence: 98%

Update on morphea

Fett¹,

Werth²

2011

Journal of the American Academy of Dermatology

154

View full text Add to dashboard Cite

show abstract

“…49,50 Treatment with twice-daily topical tacrolimus is supported by a randomized placebo-controlled trial. 52 Additional topical therapies that have shown benefit in prospective studies include topical imiquimod applied three to five times per week, 53,54 combination calcipotriol and betamethasone dipropionate applied once to twice daily, 55 and calcipotriene applied and occluded twice daily. 56 Topical steroids, anecdotally the most commonly used therapy for plaque morphea, may be effective, but to date there are no data supporting their efficacy as a solitary agent.…”

Section: Prognosismentioning

confidence: 99%

Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies

Fett¹

2013

Clinics in Dermatology

View full text Add to dashboard Cite

“…Furthermore, no patient discontinued MTX therapy due to adverse events. Over the years, many treatments of localized scleroderma have been reported, including topical and systemic corticosteroids (18,19), topical and systemic calcipotriol (18,(20)(21)(22), topical tacrolimus (23), interferon-␥ (24), phototherapy (25,26), and methotrexate (4)(5)(6)(7)(8)27,28). Only 2 double-blind placebo-controlled studies, both in adult patients, have been reported, and, perhaps because of small sample size and Type II error, neither demonstrated superior benefit of the tested treatment compared to placebo (22,24).…”

Section: Discussionmentioning

confidence: 99%

Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial

Zulian¹,

Martini²,

Vallongo³

et al. 2011

Arthritis & Rheumatism

189

151

View full text Add to dashboard Cite

Objective. Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the skin that causes permanent disability and aesthetic damage. This study was undertaken to assess the safety and efficacy of methotrexate (MTX) in the treatment of juvenile localized scleroderma.Methods. In this double-blind study, patients with active juvenile localized scleroderma were randomized (2:1) to receive oral MTX (15 mg/m 2 , maximum 20 mg) or placebo once weekly, for 12 months or until treatment failure. Both groups received oral prednisone (1 mg/kg/ day, maximum 50 mg) for the first 3 months. A target lesion was evaluated clinically, with infrared thermography and using a computerized scoring system with skin score rate (SSR) evaluation. Response to treatment was defined as the absence of new lesions, SSR <1, and a decrease in lesion temperature of at least 10% compared to baseline. Treatment failure was defined as the occurrence of new lesions, SSR >1, or increased lesion temperature. All analyses were done on the intent-totreat population.Results. Of the 85 patients screened, 70 (ages 6-17 years) were randomized (46 to the MTX group, 24 to the placebo group). The mean disease duration was 2.3 years. After an initial response in all patients, disease relapsed in 15 MTX-treated patients (32.6%) and 17 placebo-treated patients (70.8%) (P < 0.005). New lesions appeared in 3 MTX-treated patients (6.5%) versus 4 placebo-treated patients (16.7%). The mean SSR decreased from 1 to 0.79 in the MTX group and increased from 1 to 1.1 in the placebo group, and the mean target lesion temperature decreased by 44.4% in the MTX group versus 12.1% in the placebo group. Twenty-six patients in the MTX group (56.5%) and 11 patients in the placebo group (45.8%) developed mild side effects related to treatment. None of the side effects were severe enough to necessitate treatment discontinuation.Conclusion. Our findings indicate that MTX is efficacious in the treatment of juvenile localized scleroderma and is well tolerated.

show abstract

First case series on the use of calcipotriol?betamethasone dipropionate for morphoea

Cited by 51 publications

References 10 publications

Update on morphea

Update on morphea

Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies

Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial

Contact Info

Product

Resources

About